SCHEMBL4373687

SCHEMBL4373687

NC(=O)C(Cc1ccc(OC(F)(F)F)cc1)NC(=O)c1ccc(Oc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.51
MAPK14 Q16539 2/20 0.49
KLKB1 P03952 1/20 0.49
USP30 Q70CQ3 1/20 0.47
EPHX2 P34913 3/20 0.46
NR1H4 Q96RI1 1/20 0.46
PPARG P37231 2/20 0.46
PPARA Q07869 2/20 0.46
HPGDS O60760 2/20 0.45
MAOB P27338 1/20 0.44
SCN9A Q15858 1/20 0.44
PTPN1 P18031 3/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA9 Q16790 1/20 0.44
GPR132 Q9UNW8 1/20 0.44
FPR2 P25090 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364518 0.90 FPR2 (0.55) TRPV1MAPK14KLKB1USP30EPHX2
SCHEMBL4372359 0.87 USP30 (0.54) TRPV1MAPK14KLKB1USP30EPHX2
SCHEMBL5926412 0.87 FPR2 (0.52) TRPV1MAPK14KLKB1USP30EPHX2
SCHEMBL4366294 0.84 CTSL (0.52) TRPV1MAPK14KLKB1USP30EPHX2
SCHEMBL4369909 0.84 CTSL (0.52) TRPV1MAPK14KLKB1USP30EPHX2
SCHEMBL5926737 0.83 FPR2 (0.55) TRPV1KLKB1USP30EPHX2PPARG
SCHEMBL5926235 0.83 FPR2 (0.55) TRPV1KLKB1USP30EPHX2PPARG
SCHEMBL4368574 0.83 KLKB1 (0.51) KLKB1USP30EPHX2NR1H4PPARG
SCHEMBL4374870 0.83 KLKB1 (0.51) KLKB1USP30EPHX2NR1H4PPARG
SCHEMBL4368099 0.82 KLKB1 (0.51) TRPV1KLKB1USP30EPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 TRPV1 2092/4885MAPK14 1716/4885KLKB1 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.